Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Neoplasms 2Neoplasm Metastasis 2Melanoma 2Lymphoma 2Uveal Melanoma 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neurofibromatosis 1 1Neoplasms 1Multiple Myeloma 1Lung Neoplasms 1Leukemia, Myelomonocytic, Juvenile 1Hematologic Neoplasms 1Glioma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 10Iodine-131 8selpercatinib 5Thyrotropin Alfa 5trametinib 4dabrafenib 4Vemurafenib 4Thyroidectomy 4lenvatinib 3cabozantinib 3Transurethral Resection of Prostate 3Sunitinib 3Specimen Handling 3Sorafenib 3Radiofrequency Ablation 3Fluorodeoxyglucose F18 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3vandetanib 2entrectinib 2cobimetinib 2X-Rays 2Trastuzumab 2Thyroid (USP) 2Surgical Procedures, Operative 2Rosiglitazone 2Radiotherapy 2Nivolumab 2Lymph Node Excision 2Interviews as Topic 2Gefitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Cancer, Papillary × omipalisib × Clear all
NCT02152995 2026-04-13

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
34 enrolled 18 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡